N/A N=151 Effects of a Protein Calorie Supplement in HIV-infected Women With Tuberculosis
HIV · Tuberculosis
Primary: Change in CD4 Count — 215; 174 increase in CD4 cells/mm^3
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Efficacy of Dry Needling in Plantar Fasciitis
Fasciitis, Plantar
Primary: Ultrasonographic Evaluation of the Thickness of the Affected Plantar Fascia, in Longitudinal View. — 5.3; 4.7 millimeters
N/A N=21,618 Epidemiology Study of Malaria Transmission Intensity in Africa
Malaria · Malaria Vaccines
Primary: Number of Subjects With Plasmodium Falciparum (P. Falciparum) Parasitaemia (PFP), for Each Survey — 720; 574; 605; 345 Participants
Phase 2 N=31 Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study
Epilepsy
Primary: AUC 0-t — 7290.40; 5682.09; 8288.63 hr*ng/mL
N/A N=677 Unexpected Cardiac Arrest in Intensive Care Unit
Heart Arrest
Primary: Number of Patients With Unexpected Cardiac Arrest — 677; 30,722 Participants
Phase 3 N=317 Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Axial Spondyloarthritis · Nonradiographic Axial Spondyloarthritis · Nr-axSpA
Primary: Percentage of Subjects With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) Response Criteria Response at Week 52 — 7.0; 47.2 percentage of…
Phase 3 N=274 Hypovitaminosis D in Neurocritical Patients
Craniocerebral Trauma · Intracranial Aneurysm · Brain Neoplasms
Primary: Intent-to-treat Hospital Length-of-stay — 10.9; 9.1 days — p=0.2
Phase 3 N=250 Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea
HIV Enteropathy · Diarrhea With HIV
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs). — 189; 20 Participants
Phase 2 N=41 A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer
Castration Resistant Prostate Cancer
Primary: Number of Patients With PSA Response From Dose Escalation — 0 Participants
Phase 2 N=5 Study of Gemcabene in Adults With FPLD
Familial Partial Lipodystrophy · Hypertriglyceridemia · Fatty Liver
Primary: Change in Fasting Serum Triglyceride (at 12 Weeks) — -0.44; -20.27 percent change — p=0.517
N/A N=213 Evaluation of a Peer Coach-Led Intervention to Improve Pain Symptoms
Chronic Pain
Primary: Brief Pain Inventory (BPI) (Overall Pain Assessment) — 5.6; 5.6 units on a scale — p=0.981
N/A N=74 Cyanoacrylate and Laser and Dentin Sensitivity
Dentin Hypersensitivity · Dentin Sensitivity
Primary: Change of the Pain Sensitivity — 7.77; 7.49; 2.57; 2.36 score on a scale
N/A N=147 Utilization of the Mirror During Pelvic Exams
Pelvic Exam
Primary: Group Difference in Visual Analog Scale (VAS) on Level of Vulnerability — 13.294; 16.145 mm — p=0.270
Phase 2 N=114 N-acetylcysteine for Tobacco Use Disorder
Nicotine Dependence · Smoking
Primary: Number of Participants With Biochemically-verified Abstinence From Smoking on Days 1-3 of the Protocol. — 8; 6 Participants
Phase 3 N=381 A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.
Bipolar I Disorder · Acute Mania
Primary: Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) by Severity — 79; 86; 60; 68 Participants